Literature DB >> 28121161

Regulatory T Cell Effect on CD8+ T Cell Responses to Human Herpesvirus 8 Infection and Development of Kaposi's Sarcoma.

Lauren M Lepone1, Giovanna Rappocciolo1, Paolo A Piazza1, Diana M Campbell1, Frank J Jenkins1,2, Charles R Rinaldo1,2.   

Abstract

We assessed CD8+ T cell reactivity to human herpesvirus 8 (HHV-8; Kaposi's sarcoma [KS]-associated herpesvirus) and the role of CD4+CD25hiFoxP3+ regulatory T cells (Treg) in HHV-8- and HIV-coinfected participants of the Multicenter AIDS Cohort Study who did or did not develop KS. There were similarly low CD8+ T cell interferon-γ responses to MHC class I-restricted epitopes of HHV-8 lytic and latent proteins over 5.7 years before KS in participants who developed KS compared to those who did not. T cell reactivity to HHV-8 antigens was low relative to responses to a combination of cytomegalovirus, Epstein-Barr virus and influenza A virus (CEF) peptide epitopes, and dominant HIV peptide epitopes. There was no change in %Treg in the HHV-8- and HIV-coinfected participants who did not develop KS, whereas there was a significant increase in %Treg in HHV-8- and HIV-coinfected participants who developed KS beginning 1.8 years before development of KS. Removal of Treg enhanced HHV-8-specific T cell responses in HHV-8- and HIV-coinfected participants who did or did not develop KS, with a similar pattern observed in response to CEF and HIV peptides. Thus, long-term, low levels of anti-HHV-8 CD8+ T cell reactivity were present in both HHV-8- and HIV-coinfected men who did and did not develop KS. This was related to moderately enhanced Treg function.

Entities:  

Keywords:  HIV/AIDS pathogenesis; T cell immunity; T cells; immune response

Mesh:

Substances:

Year:  2017        PMID: 28121161      PMCID: PMC5512339          DOI: 10.1089/AID.2016.0155

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  35 in total

1.  Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.

Authors:  Dimitra Bourboulia; Diana Aldam; Dimitrios Lagos; Elizabeth Allen; Ian Williams; David Cornforth; Andrew Copas; Chris Boshoff
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

2.  Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.

Authors:  Serena K Perna; Biagio De Angelis; Daria Pagliara; Sayyeda T Hasan; Lan Zhang; Aruna Mahendravada; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Gianpietro Dotti; Barbara Savoldo
Journal:  Clin Cancer Res       Date:  2012-11-13       Impact factor: 12.531

3.  Lytic and latent antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus induce T-cell responses with similar functional properties and memory phenotypes.

Authors:  Florian Bihl; Murli Narayan; John V Chisholm; Leah M Henry; Todd J Suscovich; Elizabeth E Brown; Tania M Welzel; Daniel E Kaufmann; Tauheed M Zaman; Sheila Dollard; Jeff N Martin; Fred Wang; David T Scadden; Kenneth M Kaye; Christian Brander
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

Review 4.  Immunodeficiency-associated viral oncogenesis.

Authors:  A Pierangeli; G Antonelli; G Gentile
Journal:  Clin Microbiol Infect       Date:  2015-07-18       Impact factor: 8.067

5.  Detection of HHV-8 (human herpesvirus-8) genomes in induced peripheral blood mononuclear cells (PBMCs) from US blood donors.

Authors:  L Qu; D J Triulzi; D T Rowe; F J Jenkins
Journal:  Vox Sang       Date:  2010-09-02       Impact factor: 2.144

6.  Monofunctional and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins.

Authors:  Lauren Lepone; Giovanna Rappocciolo; Emilee Knowlton; Mariel Jais; Paolo Piazza; Frank J Jenkins; Charles R Rinaldo
Journal:  Clin Vaccine Immunol       Date:  2010-08-18

Review 7.  Immune escape of γ-herpesviruses from adaptive immunity.

Authors:  Zhuting Hu; Edward J Usherwood
Journal:  Rev Med Virol       Date:  2014-04-15       Impact factor: 6.989

8.  Ex-vivo recognition of late-lytic CD8 epitopes specific for Kaposi's sarcoma-associated herpesvirus (KSHV) by HIV/KSHV-coinfected individuals.

Authors:  Rebecca C Robey; Salvinia Mletzko; Mark Bower; Rhonda Meys; Marta Boffito; Mark Nelson; Christopher B Bunker; Frances M Gotch
Journal:  Viral Immunol       Date:  2011-06       Impact factor: 2.257

9.  CD8+ cytotoxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals.

Authors:  Q J Wang; F J Jenkins; L P Jacobson; Y X Meng; P E Pellett; L A Kingsley; K G Kousoulas; A Baghian; C R Rinaldo
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

10.  Identification of an HLA A*0201-restricted CD8(+) T-cell epitope for the glycoprotein B homolog of human herpesvirus 8.

Authors:  Qiong J Wang; Xiao-Li Huang; Giovanna Rappocciolo; Frank J Jenkins; William H Hildebrand; Zheng Fan; Elaine K Thomas; Charles R Rinaldo
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

View more
  10 in total

Review 1.  Adaptive immune responses to Kaposi's sarcoma-associated herpesvirus.

Authors:  Angela Nalwoga; Denise Whitby
Journal:  Curr Opin Immunol       Date:  2022-07-08       Impact factor: 7.268

Review 2.  The Role of Regulatory T Cells in Pulmonary Arterial Hypertension.

Authors:  Wen Tian; Shirley Y Jiang; Xinguo Jiang; Rasa Tamosiuniene; Dongeon Kim; Torrey Guan; Siham Arsalane; Shravani Pasupneti; Norbert F Voelkel; Qizhi Tang; Mark R Nicolls
Journal:  Front Immunol       Date:  2021-08-19       Impact factor: 8.786

3.  The Presence of Antibody-Dependent Cell Cytotoxicity-Mediating Antibodies in Kaposi Sarcoma-Associated Herpesvirus-Seropositive Individuals Does Not Correlate with Disease Pathogenesis or Progression.

Authors:  Lisa K Poppe; Charles Wood; John T West
Journal:  J Immunol       Date:  2020-09-30       Impact factor: 5.422

4.  Comparative transcriptome analysis of endemic and epidemic Kaposi's sarcoma (KS) lesions and the secondary role of HIV-1 in KS pathogenesis.

Authors:  Salum J Lidenge; Andrew V Kossenkov; For Yue Tso; Jayamanna Wickramasinghe; Sara R Privatt; Owen Ngalamika; John R Ngowi; Julius Mwaiselage; Paul M Lieberman; John T West; Charles Wood
Journal:  PLoS Pathog       Date:  2020-07-24       Impact factor: 6.823

Review 5.  Cells of the Innate and Adaptive Immune Systems in Kaposi's Sarcoma.

Authors:  Owen Ngalamika; Sody Munsaka
Journal:  J Immunol Res       Date:  2020-11-21       Impact factor: 4.818

6.  An expanded population of CD8dim T cells with features of mitochondrial dysfunction and senescence is associated with persistent HIV-associated Kaposi's sarcoma under ART.

Authors:  Genevieve T Clutton; Ann Marie K Weideman; Nilu P Goonetilleke; Toby Maurer
Journal:  Front Cell Dev Biol       Date:  2022-09-29

7.  Human Herpesvirus 8 Infects and Replicates in Langerhans Cells and Interstitial Dermal Dendritic Cells and Impairs Their Function.

Authors:  Giovanna Rappocciolo; Mariel Jais; Paolo A Piazza; Diana C DeLucia; Frank J Jenkins; Charles R Rinaldo
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

8.  Lack of CD8+ T-cell co-localization with Kaposi's sarcoma-associated herpesvirus infected cells in Kaposi's sarcoma tumors.

Authors:  Salum J Lidenge; For Yue Tso; Owen Ngalamika; Jaydeep Kolape; John R Ngowi; Julius Mwaiselage; Charles Wood; John T West
Journal:  Oncotarget       Date:  2020-04-28

9.  The Binary Classification Of Chronic Diseases.

Authors:  Zeev Elkoshi
Journal:  J Inflamm Res       Date:  2019-12-16

10.  Compartmentalized T cell profile in the lungs of patients with HIV-1-associated pulmonary Kaposi sarcoma.

Authors:  Tarisiro Matiza; Kathryn F Boyd; Rebecca A Lyall; Douglas S Kwon; Alan M McGregor; Suzanne Fiorillo; Thomas B Campbell; Margaret Borok; Björn Corleis
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.